(VIANEWS) – Shares of Pacific Biosciences of California (NASDAQ: PACB) rose by a staggering 10.18% to $6.17 at 10:34 EST on Monday, after three sequential sessions in a row of gains. NASDAQ is rising 3.33% to $12,131.13, after three successive sessions in a row of gains. This seems, at the moment, a very up trend trading session today.

Pacific Biosciences of California’s last close was $6.17, 83.03% below its 52-week high of $36.36.

Volume

Today’s last reported volume for Pacific Biosciences of California is 6578390 which is 1.35% above its average volume of 6490666.

Pacific Biosciences of California’s Sales

Pacific Biosciences of California’s sales growth is 17% for the present quarter and 30.3% for the next. The company’s growth estimates for the current quarter and the next is a negative 57.1% and a negative 500%, respectively.

Pacific Biosciences of California’s Revenue

Year-on-year quarterly revenue growth grew by 32.7%, now sitting on 130.51M for the twelve trailing months.

Volatility

Pacific Biosciences of California’s last week, last month’s, and last quarter’s current intraday variation average was a positive 0.26%, a negative 0.78%, and a positive 5.79%, respectively.

Pacific Biosciences of California’s highest amplitude of average volatility was 4.18% (last week), 7.16% (last month), and 5.79% (last quarter), respectively.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

Pacific Biosciences of California’s stock is considered to be oversold (<=20).

Pacific Biosciences of California’s Stock Yearly Top and Bottom Value

Pacific Biosciences of California’s stock is valued at $6.17 at 10:34 EST, way under its 52-week high of $36.36 and way above its 52-week low of $4.51.

Pacific Biosciences of California’s Moving Average

Pacific Biosciences of California’s value is way under its 50-day moving average of $7.39 and way below its 200-day moving average of $17.48.

More news about Pacific Biosciences of California (PACB).

LEAVE A REPLY

Please enter your comment!
Please enter your name here